Paid Clinical Trials in Chattanooga, TN

As of June 2026, 144 paid clinical trials are recruiting in Chattanooga, Tennessee. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

144 clinical trials

↓ Download CSV

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

for Focal Epilepsy

65 locations incl. Birmingham

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18 - 75

Code: NCT06309966·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

for Hypothyroidism

134 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18 - 75

Code: NCT06345339·Phase 2, Phase 3·Recruiting

Apply to this trial

Pivotal Trial of the Boomerang Catheter for pDVA

for Chronic Limb-Threatening Ischemia

19 locations incl. Sylmar

Sponsor: Aveera Medical, Inc.

Sex: All·Age: 18+

Code: NCT06311773·Enrolling By Invitation

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

63 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting

Apply to this trial

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

for Recurrent or Metastatic Solid Tumors

17 locations incl. Los Angeles

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06330064·Phase 2·Recruiting

Apply to this trial

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

for Neoplasms, Head and Neck

Drug: Dostarlimab

36 locations incl. Jonesboro

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06256588·Phase 3·Recruiting

Apply to this trial

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

141 locations incl. Birmingham

Sponsor: 89bio, Inc.

Sex: All·Age: 18 - 80

Code: NCT06318169·Phase 3·Recruiting

Apply to this trial

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

for Diabetes

21 locations incl. Dothan

Sponsor: Sonavex, Inc.

Sex: All·Age: 18 - 84

Code: NCT06190717·Recruiting

Apply to this trial

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

for COPD (Chronic Obstructive Pulmonary Disease)

234 locations incl. Athens

Sponsor: AstraZeneca

Sex: All·Age: 40 - 80

Code: NCT06283966·Phase 3·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

Drug: Nemtabrutinib

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting

Apply to this trial

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

for Choroidal Melanoma

36 locations incl. Birmingham

Sponsor: Aura Biosciences

Sex: All·Age: 18+

Code: NCT06007690·Phase 3·Recruiting

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

68 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting

Apply to this trial

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

for NASH With Fibrosis

Drug: Efruxifermin

205 locations incl. Birmingham

Sponsor: Akero Therapeutics, Inc

Sex: All·Age: 18 - 80

Code: NCT06215716·Phase 3·Recruiting

Apply to this trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

for Breast Cancer

Drug: Durvalumab

64 locations incl. Daphne

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06103864·Phase 3·Recruiting

Apply to this trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

148 locations incl. Dothan

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05952557·Phase 3·Recruiting

Apply to this trial

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

for Acute Coronary Syndrome

178 locations incl. Alexander City

Sponsor: DalCor Pharmaceuticals

Sex: All·Age: 45+

Code: NCT05918861·Phase 3·Recruiting

Apply to this trial

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

for Uterine Fibroids

Drug: Relugolix

120 locations incl. Mobile

Sponsor: Sumitomo Pharma Switzerland GmbH

Sex: Female·Age: 18 - 50

Code: NCT05862272·Phase 3·Recruiting

Apply to this trial

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

for Type 1 Diabetes Mellitus With Hypoglycemia

38 locations incl. Birmingham

Sponsor: Zucara Therapeutics Inc.

Sex: All·Age: 18 - 75

Code: NCT05762107·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

for Chronic Obstructive Pulmonary Disease

68 locations incl. Birmingham

Sponsor: Hoffmann-La Roche

Sex: All·Age: 40 - 90

Code: NCT05878769·Phase 3·Recruiting

Apply to this trial

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

for Multiple Myeloma

4 locations incl. Grand Rapids

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT05714839·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

390 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

129 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05774951·Phase 3·Recruiting

Apply to this trial

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

for Breast Cancer

17 locations incl. Greenbrae

Sponsor: Tolmar Inc.

Sex: All·Age: 18 - 51

Code: NCT05645536·Phase 3·Enrolling By Invitation

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

for Atrial Fibrillation (AF)

Drug: Abelacimab

150 locations incl. Birmingham

Sponsor: Anthos Therapeutics, Inc.

Sex: All·Age: 65+

Code: NCT05712200·Phase 3·Recruiting

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for Atherosclerotic Cardiovascular Disease in Patients With ESKD

Drug: Clazakizumab

164 locations incl. Decatur

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting

Apply to this trial

You and Me Healthy

for COVID-19

3 locations incl. Merced

Sponsor: Duke University

Sex: All·Age: 2+·Accepts healthy volunteers

Code: NCT05589376·Enrolling By Invitation

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for Platinum-resistant Ovarian Cancer

Drug: Bevacizumab

31 locations incl. Mobile

Sponsor: Genelux Corporation

Sex: Female·Age: 18+

Code: NCT05281471·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

for Acute Ischemic Stroke

1 location in Chattanooga

Sponsor: Lumosa Therapeutics Co., Ltd.

Sex: All·Age: 18 - 90

Code: NCT05198323·Phase 2·Recruiting

Apply to this trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for Non-small Cell Lung Cancer (NSCLC)

21 locations incl. Orange

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05379985·Phase 1, Phase 2·Recruiting

Apply to this trial

The CONFORM Pivotal Trial

for Atrial Fibrillation

76 locations incl. Birmingham

Sponsor: Conformal Medical, Inc

Sex: All·Age: 18+

Code: NCT05147792·Recruiting

Apply to this trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

25 locations incl. Little Rock

Sponsor: AstraZeneca

Sex: All·Age: 18 - 95

Code: NCT05061550·Phase 2·Recruiting

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

227 locations incl. Alabaster

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting

Apply to this trial

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

for Cervical Cancer

134 locations incl. Goodyear

Sponsor: GOG Foundation

Sex: Female·Age: 18+

Code: NCT04831580·Recruiting

Apply to this trial

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

for Non-Small Cell Lung Cancer

Drug: Durvalumab

43 locations incl. Chandler

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05211895·Phase 3·Recruiting

Apply to this trial

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

for Stereotypical Prolonged Seizures

53 locations incl. Phoenix

Sponsor: UCB Biopharma SRL

Sex: All·Age: 12+

Code: NCT05076617·Phase 3·Enrolling By Invitation

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

for AMD

107 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 50 - 89

Code: NCT05407636·Phase 3·Recruiting

Apply to this trial

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

for Stereotypical Prolonged Seizures

66 locations incl. Phoenix

Sponsor: UCB Biopharma SRL

Sex: All·Age: 12+

Code: NCT05077904·Phase 3·Recruiting

Apply to this trial

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

for Acute Stroke

35 locations incl. Fairhope

Sponsor: DiaMedica Therapeutics Inc

Sex: All·Age: 18 - 90

Code: NCT05065216·Phase 2, Phase 3·Recruiting

Apply to this trial

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

for B-cell Malignancy

31 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT05006716·Phase 1, Phase 2·Recruiting

Apply to this trial